Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Paxlovid

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata

Almost 20% of patients with the autoimmune disease are diagnosed before the age of 18

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

FDA advisory committee backs updated COVID-19 vaccines targeting XBB variants

The XBB.1.5 variant accounted for nearly 40% of all US COVID-19 cases as of early June

- PMLiVE

NICE announces launch of digital and AI advice service for healthcare sector

Four UK healthcare organisations collaborated on the AI and Digital Regulations Service

- PMLiVE

Pfizer reports positive results for elranatamab in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections

AMR has been declared by WHO as one of the top ten threats to global health

- PMLiVE

Pfizer’s RSV vaccine approved by FDA for older adults

RSV infections in older adults account for up to 160,000 hospitalisations each year in the US

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee

Up to 80,000 children aged under five are hospitalised each year in the US due to RSV infection

Bayer symbol

Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer

More than 47,000 new cases of prostate cancer are diagnosed every year in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links